{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:41:17Z","timestamp":1792269677867,"version":"4.4.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Refractory juvenile idiopathic arthritis (JIA) remains difficult to manage, particularly in patients with persistent disease activity despite multiple conventional synthetic disease-modifying antirheumatic drugs and biologic agents. Telitacicept is a dual inhibitor of B-cell activating factor and a proliferation-inducing ligand, but its use in JIA has not been well described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report three pediatric patients with refractory JIA treated with telitacicept. Case 1 was a 6-year-old girl with extended oligoarticular JIA who presented with recurrent swelling, pain, and limited motion of multiple joints, and elevated inflammatory markers after previous treatment with methotrexate, leflunomide, adalimumab, and intra-articular glucocorticoids. After switching to telitacicept combined with tofacitinib and methotrexate, joint symptoms and inflammatory markers improved, and an ACR70 response was achieved; clinical improvement was maintained during 12 months of follow-up. Case 2 was a 17-year-old boy with RF-positive polyarticular JIA and long-standing active disease involving the wrists and small joints of the hands. After telitacicept was added to background therapy, joint swelling resolved, inflammatory markers normalized, and ACR90 response was achieved during 9 months of follow-up. Case 3 was an 11-year-old boy with systemic JIA whose systemic manifestations had been controlled but who continued to have predominant polyarticular involvement. After telitacicept initiation, wrist swelling and inflammatory markers improved during the first 2 months, and an early ACR90 response was observed; however, relapse occurred at month 3 with recurrence of systemic symptoms, leading to discontinuation of telitacicept. No serious adverse events were observed. One patient developed a mild upper respiratory tract infection that resolved with symptomatic treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These cases provide preliminary clinical observations on telitacicept use in refractory JIA. BAFF\/APRIL inhibition may warrant further investigation in selected patients with refractory JIA, particularly those with persistent articular involvement; however, prospective controlled studies are needed to evaluate efficacy and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1846557","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:35:25Z","timestamp":1785216925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Telitacicept in the treatment of refractory juvenile idiopathic arthritis: clinical experience from three cases"],"prefix":"10.3389","volume":"14","author":[{"given":"Xiya","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents'Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents'Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents'Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12969-023-00897-6","article-title":"Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis","volume":"21","author":"Pedersen","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR Points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"103291","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J Autoimmun"},{"key":"B4","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1080\/07853890.2022.2095431","article-title":"Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives","volume":"54","author":"Ambler","year":"2022","journal-title":"Ann Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1093\/rheumatology\/keab237","article-title":"Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review","volume":"60","author":"Chaplin","year":"2021","journal-title":"Rheumatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0312174","DOI":"10.1371\/journal.pone.0312174","article-title":"Treatment of refractory poly articular course juvenile idiopathic arthritis with tofacitinib: extended experience from Bangladesh","volume":"20","author":"Iman","year":"2025","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"103248","DOI":"10.1016\/j.jaut.2024.103248","article-title":"JAK Inhibitors in refractory juvenile rheumatic diseases: efficacy, tolerance and type-I interferon profiling, a single center retrospective study","volume":"147","author":"Solignac","year":"2024","journal-title":"J Autoimmun"},{"key":"B10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/bloodadvances.2017014449","article-title":"Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis","volume":"2","author":"M. F. Silva","year":"2018","journal-title":"Blood Advances"},{"key":"B11","doi-asserted-by":"publisher","first-page":"152774","DOI":"10.1016\/j.semarthrit.2025.152774","article-title":"The effectiveness and safety of rituximab in juvenile idiopathic arthritis: hints from the ITHACA monocentric registry","volume":"74","author":"Pellico","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40884","article-title":"2019 American college of rheumatology\/arthritis foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1136\/ard-2024-225851","article-title":"EULAR\/PReS recommendations for the diagnosis and management of Still's Disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's Disease","volume":"83","author":"Fautrel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.autrev.2011.02.001","article-title":"The pathogenesis of oligoarticular\/polyarticular vs systemic juvenile idiopathic arthritis","volume":"10","author":"Lin","year":"2011","journal-title":"Autoimmun Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/art.41107","article-title":"Innately adaptive or truly autoimmune: is there something unique about systemic juvenile idiopathic arthritis?","volume":"72","author":"Kessel","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"851532","DOI":"10.3389\/fmed.2022.851532","article-title":"B cells on the stage of inflammation in juvenile idiopathic arthritis: leading or supporting actors in disease pathogenesis?","volume":"9","author":"Moura","year":"2022","journal-title":"Front Med (Lausanne"},{"key":"B17","doi-asserted-by":"publisher","first-page":"15785","DOI":"10.1073\/pnas.1521837113","article-title":"Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis","volume":"112","author":"Nigrovic","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17050","DOI":"10.1002\/jcp.28445","article-title":"The role of BAFF and APRIL in rheumatoid arthritis","volume":"234","author":"Shabgah","year":"2019","journal-title":"J Cell Physiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jbspin.2011.05.020","article-title":"Elevated BAFF (BLyS) and APRIL in Juvenile idiopathic arthritis patients: relation to clinical manifestations and disease activity","volume":"79","author":"Gheita","year":"2012","journal-title":"Joint Bone Spine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/rheumatology\/keq338","article-title":"Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival","volume":"50","author":"Moura","year":"2011","journal-title":"Rheumatology (Oxford"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bcp.12908","article-title":"Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS\/APRIL fusion protein, in patients with rheumatoid arthritis","volume":"82","author":"Chen","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B23","article-title":"Telitacicept, a human recombinant fusion protein targeting and neutralizing B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL), in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate (MTX): a randomized, double-blind, phase 3 study [abstract]","volume":"75","author":"Wang","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1558059","DOI":"10.3389\/fimmu.2025.1558059","article-title":"Case report: a refractory unusual tetrad of overlap syndrome involving rheumatoid arthritis, Sj\u00f6gren's Syndrome, autoimmune hepatitis, and type 1 renal tubular acidosis, successfully treated with a BLyS\/APRIL dual inhibitor","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"rxaf074","DOI":"10.1093\/mrcr\/rxaf074","article-title":"Successful treatment of rheumatoid arthritis complicated with myasthenia gravis by telitacicept: a case report","volume":"9","author":"Qiu","year":"2025","journal-title":"Mod Rheumatol Case Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/09612033221097812","article-title":"Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before\u2013after trial","volume":"31","author":"Sun","year":"2022","journal-title":"Lupus"},{"key":"B28","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/art.43417","article-title":"The efficacy of telitacicept in childhood-onset systemic lupus erythematosus: a prospective multi-center cohort study with IPTW-adjusted comparison to a historical control group treated with belimumab","volume":"78","author":"Luo","year":"2025","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1846557\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:35:27Z","timestamp":1785216927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1846557\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":28,"alternative-id":["10.3389\/fped.2026.1846557"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1846557","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1846557"}}